Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corp. is a U.S.-based medical technology company focused on surgical, neurosurgical, ENT, and regenerative care products. It sells devices and biologic materials used to restore tissue, support wound healing, and enable precision surgery, with two main segments: Codman Specialty Surgical and Tissue Technologies.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaMarket-leading surgical instruments and technologies for neurosurgery, neurocritical care, ENT, and other precision procedures.
Regenerative tissue products for wound reconstruction, wound care, and reconstructive surgery, including biologic materials.
Manufactured regenerative and wound care products sold to other medical technology companies under their own brands.
Products used in burn care, deep tissue wounds, plastic surgery, and soft tissue repair.
Tools and instrumentation used across precision, specialty, and general surgical procedures.
Asiakkaat
Integra sells primarily to hospitals, integrated health networks, group purchasing organizations, surgery centers, and clinicians through direct sales and distributors. Demand is driven by surgeons and care teams in neurosurgery, ENT, wound care, and reconstructive procedures that require specialized products and clinical support.
Buy neurosurgical, ENT, and wound care products for inpatient procedures and standardized clinical pathways.
Use specialty instruments and regenerative products in procedures that require precision and trusted performance.
Source products for member hospitals and health systems to manage cost and supply consistency.
Purchase specialty surgical tools and wound products for outpatient and ambulatory procedures.
Buy collagen biomaterials and manufactured components for their own branded end-market products.
Strategia
Integra is focused on fixing operations, improving quality systems, and expanding manufacturing capacity to support more reliable supply and lower costs. It is also investing in new product development, clinical evidence, and market access to strengthen its neurosurgery, ENT, and regenerative care franchises.
Quality and supply issues can disrupt shipments, raise costs, and damage customer trust.
More resilient manufacturing supports product availability and reduces single-site risk.
Clinical proof and reimbursement support are key to adoption in surgical and regenerative care.
Broader geographic reach diversifies demand and supports growth beyond the U.S. market.
Maantiede
Integra generates most revenue in the United States, with meaningful exposure to Europe, Asia Pacific, and the rest of the world. The company also operates manufacturing and distribution sites across North America, Europe, China, Japan, and Israel, and it has been expanding in Southeast Asia, India, South Korea, and Brazil.
Riskit
Integra is exposed to operational and quality execution risk because its products depend on regulated manufacturing, validated processes, and reliable supply. It also faces macro, geopolitical, and foreign exchange risk from its global footprint, plus impairment risk after a large goodwill charge tied to weaker performance and market uncertainty.
- Quality and manufacturing execution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company is remediating quality system gaps and transferring production across sites, which can interrupt supply and raise costs.
Kohdistuu - Global macroeconomic and geopolitical riskVaikutus: KorkeaTodennäköisyys: Korkea
Tariffs, trade barriers, inflation, and geopolitical instability can affect sourcing, pricing, and customer demand.
Kohdistuu - Goodwill and intangible asset impairmentVaikutus: KorkeaTodennäköisyys: Korkea
Management recorded a large goodwill impairment in 2025, showing sensitivity to valuation assumptions and operating performance.
Kohdistuu - Foreign exchange and interest rate riskVaikutus: KeskitasoTodennäköisyys: Korkea
A meaningful share of revenue and costs is outside the U.S., and borrowing costs have risen.
Kohdistuu: Foreign currency translation and debt servicing
- Cybersecurity and IT systems disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
A breach or outage could interrupt transaction processing, manufacturing, and product supply.
Kohdistuu: Enterprise business systems and third-party vendors
Kirjanpito
Harkinnanvaraiset erätA $511.4 million charge in 2025 shows that reporting unit valuations are highly sensitive to market and operating assumptions.
Vaikutus: Can materially reduce earnings and book value without affecting cash flow
Revenue is assigned to customer location, which affects reported regional mix and exposure analysis.
Vaikutus: Important for understanding U.S. concentration and international growth
Capacity moves, quality remediation, and integration efforts can create one-time or recurring charges.
Vaikutus: Can obscure underlying operating trends
Effective tax rates are influenced by non-deductible impairment, GILTI, and global minimum tax rules.
Vaikutus: Can cause volatility in reported tax expense
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
TELA Bio, Inc.
TELA · Surgical & Medical Instruments & Apparatus
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
BioScience Health Innovations, Inc.
BHIC · Services-Computer Processing & Data Preparation
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Päivitetty: 24.9.2026